Ainos, Inc.: Ainos Pursues Licensing Partners to Accelerate Five Candidates of its Low-dose Oral Interferon Formulation VELDONA to Phase 3 Trials and Commercialization

Clinical results thus far have shown low-dose oral interferon's promising efficacy as a new treatment or as an alternative to high-dose injectable interferonSAN DIEGO, CA / ACCESSWIRE / October 31, 2022

Related Keywords

California ,United States ,San Diego ,Robin Yang ,Exchange Commission ,Company Form ,Ainos Inc ,Ainos Inc View ,Amarillo Biosciences Inc ,Nasdaq ,Aphthous Stomatitis ,Common Cold ,Hsien Tsai ,Aino Chairman ,Chief Executive Officer ,Amarillo Biosciences ,Volatile Organic Compounds ,Securities Litigation Reform Act ,Annual Report ,Inc View ,Kainos ,Spursues ,Icensing ,Partners ,Ccelerate ,Five ,Candidates ,Nose ,Mural ,Interferon ,Formulation ,Weldona ,Hase ,Trials ,Ommercialization ,